Joule Unlimited, Inc.

Joule Names John Ward Senior Vice President of Production

Joule Names John Ward Senior Vice President of Production

July 20, 2010

Cambridge, Mass. – July 20, 2010 – Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today announced the appointment of John Ward as Senior Vice President of Production, overseeing the company's scale-up planning, direction and construction as it advances towards commercial production of solar-derived, renewable fuels and chemicals. This will include management of Joule’s site selection and related partnerships with CO2 emitters to drive Joule's process, as well as assisting in the deployment of commercialization partners' production facilities.

TARIS Biomedical, Inc.

TARIS Appoints Sarma Duddu as President and CEO

TARIS Appoints Sarma Duddu as President and CEO

July 19, 2010

Accomplished Pharmaceutical Executive

Lexington, MA – July 19, 2010 – TARIS Biomedical , a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced that Sarma Duddu, Ph.D. has been named President and Chief Executive Officer and a member of the Board of Directors, effective immediately.

Novomer, Inc.

Novomer Selected for DOE Grant

Novomer Selected for DOE Grant

July 22, 2010

Secretary Chu Announces Six Projects to Convert Captured CO2 Emissions from Industrial Sources into Useful Products

$106 Million Recovery Act Investment will Reduce CO2 Emissions and Mitigate Climate Change

Tetraphase Pharmaceuticals, Inc.

TetraPhase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections

TetraPhase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections

November 24, 2006

Company Completes $25M Series A Financing

Watertown and Cambridge MA, November 24, 2006 - TetraPhase Pharmaceuticals Inc. and Harvard University’s Office of Technology Development (OTD) announced today the formation of a biotechnology company that will develop new classes of antibiotics aimed at drug-resistant infections. The Company’s approach capitalizes on ground-breaking technology and patents licensed from Harvard University.

Adnexus Therapeutics

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director

November 28, 2006

Accomplished Drug Development Physician to Drive Clinical Advancement of Maturing Adnectin™ Product Pipeline

Waltham, MA, November 28, 2006 – Adnexus TherapeuticsTM today announced the expansion of its management team with the appointment of Bruce A. Silver, MD, FACP to the newly-created role of Medical Director. The advancement into Phase 2 of CT-322, the company’s lead product that is currently in Phase 1 development in oncology, will be among Dr. Silver’s responsibilities.

BIND Therapeutics, Inc.

BIND Biosciences Secures $12.4 Million Financing

BIND Biosciences Secures $12.4 Million Financing

June 29, 2010

Series C-1 Financing Enables BIND To Pursue Multi-product Strategy

BIND Therapeutics, Inc.

BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

June 29, 2010

Brings Clinical Leadership as BIND Prepares for Product Candidates to Enter the Clinic

Helicos BioSciences Corporation

Helicos BioSciences Announces Launch of Diagnostics Business

Helicos BioSciences Announces Launch of Diagnostics Business

June 25, 2010

CAMBRIDGE, Mass., Jun 25, 2010 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it is in the early stages of validating molecular diagnostic (MDx) tests that utilize its HeliScope(R) Single Molecule Sequencer. The HeliScope Sequencer's ability to sequence single molecules of natural, unamplified DNA or RNA simplifies the diagnostic testing workflow obviating the need for the amplification steps utilized by most genetic analysis methods.

Mascoma Corporation

Mascoma and Tamarack Energy Partner to Accelerate the Commercialization of Cellulosic Ethanol

Mascoma and Tamarack Energy Partner to Accelerate the Commercialization of Cellulosic Ethanol

November 29, 2006

Plans Underway to Open Facilities with Initial Focus on the State of New York

VisEn Medical, Inc.

VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

November 29, 2006

Woburn, MA November 29, 2006 VisEn Medical, Inc. today announced that it has entered into a joint research program to expand the capabilities and accelerate the adoption of VisEn's in vivo fluorescence technologies in Eli Lilly and Companys research and development programs. Lilly has been working with VisEn's portfolio of in vivo fluorescence probes and Fluorescence Molecular Tomography (FMT) imaging systems as part of their new molecular imaging center and preclinical development programs.